{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-157311","form_type":"8-K","ticker":"KLRS","cik":"0001754068","company_name":"Kalaris Therapeutics, Inc.","filed_at":"2024-06-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.897518+00:00","generated_at":"2026-06-01T05:38:14.998082+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"AlloVir stockholders elect three Class I directors and ratify Deloitte as auditor at 2024 annual meeting","bullets":["Elected Juan Vera (77.7M for, 4.2M withhold), Morana Jovan-Embiricos (76.2M for, 5.8M withhold), Derek Adams (76.2M for, 5.7M withhold) as Class I directors.","Ratified Deloitte & Touche as independent auditor for FY2024: 104.2M for, 276K against, 400K abstain.","Broker non-votes totaled 22,994,115 on each director election; no other matters voted on.","Meeting held June 6, 2024; record date April 15, 2024 with 114,912,515 shares outstanding."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-157311","json":"https://secwatch.observer/filing/0001193125-24-157311.json","markdown":"https://secwatch.observer/filing/0001193125-24-157311.md","text":"https://secwatch.observer/filing/0001193125-24-157311.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1754068/000119312524157311/0001193125-24-157311-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1754068/000119312524157311/d796921d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T05:38:14.998082+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}